Sugi Predict

Sugi Predict / Compounds / SCHEMBL641413

SCHEMBL641413

SCHEMBL641413

CCCCCCCCCCCCC/C=C/C(O)CCO

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SPHK2 Q9NRA0 4/20 0.56
▸ SPHK1 Q9NYA1 4/20 0.56
▸ CETP P11597 4/20 0.56
▸ MEN1 O00255 5/20 0.54
▸ KMT2A Q03164 5/20 0.54
▸ MAPT P10636 3/20 0.54
▸ THRB P10828 3/20 0.54
▸ GMNN O75496 2/20 0.54
▸ LMNA P02545 2/20 0.54
▸ GLA P06280 2/20 0.54
▸ POLB P06746 2/20 0.54
▸ MAPK1 P28482 2/20 0.54
▸ CXCR5 P32302 2/20 0.54
▸ CCR6 P51684 2/20 0.54
▸ BLM P54132 2/20 0.54
▸ UBE2N P61088 2/20 0.54
▸ CYP2D6 P10635 2/20 0.54
▸ ALDH1A1 P00352 2/20 0.54
▸ TP53 P04637 1/20 0.54
▸ CYP1A2 P05177 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22986945 1.00 SPHK2 (0.56) SPHK2SPHK1CETPMEN1KMT2A
SCHEMBL12279939 1.00 SPHK2 (0.56) SPHK2SPHK1CETPMEN1KMT2A
SCHEMBL30145014 1.00 SPHK2 (0.56) SPHK2SPHK1CETPMEN1KMT2A
SCHEMBL641414 1.00 SPHK2 (0.56) SPHK2SPHK1CETPMEN1KMT2A
SCHEMBL22910799 1.00 SPHK2 (0.56) SPHK2SPHK1CETPMEN1KMT2A
SCHEMBL7124765 0.92 SPHK2 (0.46) SPHK2SPHK1CETPMEN1KMT2A
SCHEMBL7124766 0.92 SPHK2 (0.46) SPHK2SPHK1CETPMEN1KMT2A
SCHEMBL28512851 0.91 SPHK2 (0.54) SPHK2SPHK1CETPMEN1KMT2A
SCHEMBL3696093 0.89 PPARG (0.55) SPHK2SPHK1CETPMEN1KMT2A
SCHEMBL11855470 0.88 PPARG (0.61) SPHK2SPHK1CETPMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12565513-B2 Synthesis of glycosphingolipids UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2026-03-03 — — US disclosed
US-11820789-B2 Glycosylated sphingoid bases and production thereof CARBOCODE S.A. (PT) 2023-11-21 — — US disclosed
US-20230094369-A1 SYNTHESIS OF GLYCOSYLATED SPHINGOID BASES OF INTEREST OR ANALOGUES THEREOF CARBOCODE S A (PT) 2023-03-30 — — US disclosed
US-20220340612-A1 SYNTHESIS OF GLYCOSPHINGOLIPIDS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. 2022-10-27 — — US disclosed
CN-115151651-A Synthesis of glycosylated sphingosine base of interest or analogues thereof 碳码股份公司 2022-10-04 — — CN disclosed
US-20180289670-A1 COMBINATION OF LBH589 WITH OTHER THERAPEUTIC AGENTS FOR TREATING CANCER NOVARTIS AG (CH) 2018-10-11 — — US disclosed
EP-3348265-A1 TUBEROUS SCLEROSIS TREATMENT Novartis AG (CH) 2018-07-18 — — EP disclosed
US-20180071251-A1 COMBINATION OF LBH589 WITH OTHER THERAPEUTIC AGENTS FOR TREATING CANCER NOVARTIS AG (CH) 2018-03-15 — — US disclosed
EP-1983984-B1 TUBEROUS SCLEROSIS TREATMENT NOVARTIS AG (CH) 2018-03-07 — — EP disclosed
US-20170246147-A1 COMBINATION OF LBH589 WITH OTHER THERAPEUTIC AGENTS FOR TREATING CANCER NOVARTIS AG (CH) 2017-08-31 — — US disclosed
WO-2007096174-A1 RAPAMYCIN DERIVATIVES FOR TREATING NEUROBLASTOMA NOVARTIS AG (CH) 2007-08-30 — — WO disclosed
WO-2007088034-A2 TUBEROUS SCLEROSIS TREATMENT NOVARTIS AG (CH) 2007-08-09 — — WO disclosed
WO-2007080124-A1 COMBINATION OF MTOR INHIBITOR AND ANTIPOLATE COMPOUND NOVARTIS AG (CH) 2007-07-19 — — WO disclosed
WO-2007071440-A1 INHIBITORS OF CCR9 ACTIVITY NOVARTIS AG (CH) 2007-06-28 — — WO disclosed
WO-2007071443-A1 INHIBITORS OF CCR9 ACTIVITY NOVARTIS AG (CH) 2007-06-28 — — WO disclosed
WO-2007071442-A2 INHIBITORS OF CCR9 ACTIVITY NOVARTIS AG (CH) 2007-06-28 — — WO disclosed
US-20070082855-A1 Pharmaceutical formulations employing short-chain sphingolipids and their use HET NEDERLANDS KANKER INSTITUUT (NL) 2007-04-12 — — US disclosed
EP-1686959-A2 PHARMACEUTICAL FORMULATIONS EMPLOYING SHORT-CHAIN SPHINGOLIPIDS AND THEIR USE HET NEDERLANDS KANKER INSTITUUT (The Netherlands Cancer Institute) (NL) 2006-08-09 — — EP disclosed
WO-2005046637-A2 PHARMACEUTICAL FORMULATIONS EMPLOYING SHORT-CHAIN SPHINGOLIPIDS AND THEIR USE HET NEDERLANDS KANKER INSTITUUT (NL) 2005-05-26 — — WO disclosed
EP-0372571-A2 Novel sphingenine and derivatives thereof MECT CORPORATION (JP) 1990-06-13 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11820789-B2 Glycosylated sphingoid bases and production thereof UGCG, CERT1, SGMS1 SPHK2 15/4885SPHK1 13/4885CETP 915/4885
US-20220340612-A1 SYNTHESIS OF GLYCOSPHINGOLIPIDS UGCG, ST6GAL1, MAGT1 SPHK2 230/4885SPHK1 235/4885CETP 265/4885
US-20180071251-A1 COMBINATION OF LBH589 WITH OTHER THERAPEUTIC AGENTS FOR TREATING CANCER MCL1, BAD, LPXN SPHK2 887/4885SPHK1 1201/4885CETP 3641/4885
US-20170246147-A1 COMBINATION OF LBH589 WITH OTHER THERAPEUTIC AGENTS FOR TREATING CANCER MCL1, BAD, LPXN SPHK2 887/4885SPHK1 1201/4885CETP 3641/4885
US-20070082855-A1 Pharmaceutical formulations employing short-chain sphingolipids and their use SGMS1, SGMS2, CERT1 SPHK2 25/4885SPHK1 17/4885CETP 22/4885
US-12565513-B2 Synthesis of glycosphingolipids UGCG, GALC, TREH SPHK2 1145/4885SPHK1 1540/4885CETP 64/4885
US-20180289670-A1 COMBINATION OF LBH589 WITH OTHER THERAPEUTIC AGENTS FOR TREATING CANCER MCL1, BAD, LPXN SPHK2 887/4885SPHK1 1201/4885CETP 3641/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.